Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses.
|
| Abstract |
Virus-like particles (VLP) are effective vehicles for delivery of heterologous antigen to antigen-presenting cells. However VLP alone are insufficiently stimulatory to generate the signals required to facilitate effective priming of naïve T cells. We show that the VLP derived from rabbit hemorrhagic disease virus can bind the galactose-containing adjuvant α-galactosylceramide to form a composite particle for co-delivery of antigen and adjuvant to the same antigen-presenting cell. Vaccination with VLP and α-galactosylceramide activated splenic iNKT cells to produce IFN-γ and IL-4, led to the generation of antigen-specific T cells that protected prophylactically against subcutaneous tumor challenge, and was more effective at generating anti-tumor immune responses than either component individually. These data demonstrate a novel method for immunopotentiating VLP to increase their efficacy in the generation of anti-tumor responses via the innate ligand recognition properties of calicivirus-derived nanoparticles.
|
|---|---|
| Authors | Sara J McKee, Vivienne L Young, Fiona Clow, Colin M Hayman, Margaret A Baird, Ian F Hermans, Sarah L Young, Vernon K Ward |
| Journal | Journal of controlled release : official journal of the Controlled Release Society (J Control Release) Vol. 159 Issue 3 Pg. 338-45 (May 10 2012) ISSN: 1873-4995 [Electronic] Netherlands |
| PMID | 22386518 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't) |
| Copyright | Copyright © 2012 Elsevier B.V. All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!